Open Accessibility Menu

Coronavirus (COVID-19) Vaccine Update Click here to learn more.

For information about COVID-19 or to view additional resources, please click here.

Transcranial Magnetic Stimulation

Depression & ANXIETY Treatment in Washington DC

We are glad to offer transcranial magnetic stimulation (TMS) at The GW Medical Faculty Associates as a treatment of depression and anxiety.

Transcranial magnetic stimulation (TMS) is a noninvasive procedure that stimulates brain cells using magnetic fields to improve symptoms of depression and anxiety. TMS is usually used when other treatments for depression or anxiety such as medications and psychotherapy have failed.

During a TMS session, an electromagnetic coil is placed near your forehead on your scalp. In a painless way, the coil delivers pulses of magnetic fields stimulating brain cells involved in mood control, depression and anxiety.

Because the treatment for depression involves using repetitive pulses for each session, it is called repetitive TMS (rTMS).

What to Expect

TMS sessions are carried out daily for 4-6 weeks. Each session will last for 20-40 minutes. The first session will typically last longer, around 60 minutes, as the physician has to determine the optimal site and the amount of magnetic energy needed for stimulation. This process is called mapping and is usually repeated every 2 weeks.

TMS is well tolerated and safe. However, some patients could experience some side effects.

Common side effects include: lightheadedness, headache, scalp discomfort, tingling or twitching of the facial muscles.

These side effects are usually mild and tend to improve with every subsequent session.

Serious side effects are very uncommon and include seizures, hearing loss (if there is inadequate ear protection during the sessions) and mania (in people with bipolar disorder).

You will need a referral from the physician treating your depression or anxiety and follow-up with the same physician to see if you are benefiting from the treatment.

What You Should Know

Symptom relief may take few weeks of treatment. Repetitive TMS (rTMS) is less likely to work if the mental illness includes psychotic symptoms, failure to respond to electroconvulsive therapy (ECT) and refractory chronic depression that has been lasting for many years.

Contraindications for TMS include the presence of any metallic or medical implanted device close enough to the electromagnetic coil such as aneurysm clips or coils and deep brain stimulators, pregnancy and a history of seizures.

If you suffer from depressive symptoms and are deemed a good candidate for rTMS by your referring physician, we look forward to seeing you in our TMS lab to help you.

Contact Us

Call (202) 677-6823 for more information.

Conveniently Located

Clinical Trials

  • Phase 3 ALS study (CY 5031) with reldesemtiv. (Cytokinetics)
    This is a Phase 3, double-blind, randomized, placebo-controlled trial of reldesemtiv in patients aged 18 to 80 with ALS to assess the effect of reldesemtiv versus placebo on functional outcomes in ALS
  • Food as Medicine to Improve Lifestyle for Stroke Patients (FAMILY (CAFB))
    The purpose of this study is to evaluate if groceries delivered every two weeks, along with nutrition education and nutrition counseling, will improve the health of individuals who have recently had a stroke.
  • Sleep for Stroke Management And Recovery Trial (SleepSmart)
    Investigator-initiated, phase 3 multicenter, prospective randomized open-, blinded-endpoint (PROBE) controlled trial to test whether treatment of obstructive sleep apnea (OSA) with continuous positive airway pressure is effective for secondary prevention and recovery after stroke.
  • Preventative treatment of migraine: Outcomes for patients in realy-world healthcare systems (Triumph)
    This study is a 24-month prospective, multicenter, international, 2-stage noninterventional study reflecting treatment within real-world settings of patients with migraine who are switching or initiating pharmacologic treatment for migraine prevention
  • A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab in Patients with Migraine in Routine Clinical Practice (TV48125)
    A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab in Patients with Migraine in Routine Clinical Practice
  • A 12 month prospective, randomized, interventional, global, multicenter, active-controlled study comparing sustained benefit of two treatment paradigms (erenumab qm vs oral prophylactics) in adult episodic migraine patients (AMG334A2401)
    This study uses a single-cohort, 2-treatment arm (erenumab versus oral SoC prophylactic treatment), parallel-group randomized (2:1 [erenumab (70mg or 140mg): SoC oral prophylactic]), open-label design in adult patients with episodic migraine who have previously failed 1 or 2 prophylactic migraine treatments.
  • A phase 4, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of erenumab in adults with chronic migraine and medication overuse headache (Amgen20170703)
    Study 20170703 is a phase 4, randomized, double-blind, double-dummy, parallel-group, placebo-controlled study to evaluate the safety and efficacy of erenumab against placebo in a CM population with MOH and prior history of treatment failure.
  • A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety and tolerability of atogepant for the prevention of chronic migraine (Allergan3101-303-002)
    Multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the safety and tolerability of atogepant 30 mg twice per day (BID) and 60 mg once daily for the prevention of chronic migraine (CM).
  • A phase 2, randomized, placebo-controlled study to evaluate the safety, tolerability and efficacy of TAK-079 in patients with generalized myasthenia gravis (TAK079-1005)
    This is a phase 2, randomized, double-blind, placebo-controlled study designed to assess the safety, tolerability, and efficacy of TAK-079 in patients with generalized MG in combination with standard background therapy.
  • A phase 3, randomized, double-blind, placebo-controlled study evaluating efficacy and safety of rozanolixizumab in adult patients with generalized myasthenia gravis (UCB MG0003)
    This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled, 3-arm, repeat dose study evaluating the efficacy and safety of two doses of rozanolixizumab and matching placebo in patients with generalized MG who experience moderate to severe symptoms (Myasthenia Gravis Foundation of America [MGFA II-IVa]) and are being considered for additional treatment such as IVIg or PEX
  • A phase II study to evaluate the safety and tolerability of pyridostigmine when given with ondansetron to subjets with anti-AChR postive myasthenia gravis (DAS-MG)
    This is a phase II, single center, randomized, double-blind, placebo-controlled, study in patients with a diagnosis of anti-AchR antibody positive myasthenia gravis to compare the gastrointestinal (GI) side effects of pyridostigmine alone and when given with ondansetron in patients with a known diagnosis of anti-AchR antibody positive myasthenia gravis and current (i.e., past 7 days) pyridostigmine-related GI side effects
  • A phase 3, multicenter, open-label extension study of Zilucoplan in subjects with generalized myasthenia gravis (RA Pharma 302: Raise XT)
    Study RA101495-02.302 is a multicenter, open-label extension study to evaluate the long-term efficacy, safety, and tolerability of zilucoplan in subjects with gMG who have previously participated in a qualifying Ra Pharmaceuticals sponsored zilucoplan study. The visit schedule during the first 12 weeks of Study RA101495-02.302 (RAISE)